Why is it not recommended to take dasatinib/staxacil?

Dasatinib (Dasatinib) is a broad-spectrum tyrosine kinase inhibitor mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and certain types of acute lymphoblastic leukemia (Ph+ ALL). Although its efficacy is significant, not all patients are suitable for use, so there are certain contraindications and safety risks that require careful evaluation. First of all, dasatinib may cause cardiovascular adverse reactions, including arrhythmia, QT interval prolongation, and heart failure. Its use is not recommended for patients with previous severe heart disease or heart failure. At the same time, dasatinib can cause pulmonary arterial hypertension (PAH) and interstitial lung disease. These pulmonary complications may occur or aggravate the original pulmonary dysfunction during treatment. Therefore, patients with respiratory diseases need to strictly assess the risks.

In addition, dasatinib may affect bone marrow hematopoietic function, leading to a decrease in neutrophil, platelet, and red blood cell counts, and increasing the risk of infection and bleeding. Especially for patients with unstable hemograms or recent myelosuppressive therapy, blind use may pose safety risks. Patients with hepatic and renal insufficiency also need to be cautious, as drug metabolism and excretion may be affected, increasing the probability of toxic reactions. It is also not recommended for use by pregnant and lactating women as indasatinib may have adverse effects on the fetus and infant, including potential growth disorders and congenital risks.

Therefore, although dasatinib has obvious efficacy in the treatment of Ph+ CML and related leukemias, it is not recommended to be taken blindly or on your own due to its potential serious adverse reactions and contraindications for certain groups of people. Patients must be evaluated by a hematology specialist before use, including heart, lung function, liver and kidney function tests, and be monitored regularly during treatment to ensure a balance between safety and efficacy.

Reference materials:https://go.drugbank.com/drugs/DB01254